{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T05:40:25Z","timestamp":1794375625991,"version":"4.9.0"},"reference-count":228,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1038\/s41584-026-01406-1","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T10:39:46Z","timestamp":1785839986000},"page":"541-557","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Advances in the treatment of eosinophilic granulomatosis with polyangiitis"],"prefix":"10.1038","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3070-2949","authenticated-orcid":false,"given":"Adrien","family":"Cottu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5288-0375","authenticated-orcid":false,"given":"Florence","family":"Roufosse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allyson","family":"Egan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9575-8321","authenticated-orcid":false,"given":"Giacomo","family":"Emmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthieu","family":"Groh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra M.","family":"Nanzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6559-1206","authenticated-orcid":false,"given":"Ulrich","family":"Specks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E.","family":"Wechsler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3814-9172","authenticated-orcid":false,"given":"Augusto","family":"Vaglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Terrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,4]]},"reference":[{"key":"1406_CR1","first-page":"277","volume":"27","author":"J Churg","year":"1951","unstructured":"Churg, J. & Strauss, L. Allergic granulomatosis, allergic angiitis, and periarteritis nodosa. Am. J. Pathol. 27, 277\u2013301 (1951).","journal-title":"Am. J. Pathol."},{"key":"1406_CR2","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1002\/art.1780370206","volume":"37","author":"JC Jennette","year":"1994","unstructured":"Jennette, J. C. et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum. 37, 187\u2013192 (1994).","journal-title":"Arthritis Rheum."},{"key":"1406_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/art.37715","volume":"65","author":"JC Jennette","year":"2013","unstructured":"Jennette, J. C. et al. 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides. Arthritis Rheum. 65, 1\u201311 (2013).","journal-title":"Arthritis Rheum."},{"key":"1406_CR4","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1002\/art.37721","volume":"65","author":"C Comarmond","year":"2013","unstructured":"Comarmond, C. et al. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort. Arthritis Rheum. 65, 270\u2013281 (2013).","journal-title":"Arthritis Rheum."},{"key":"1406_CR5","doi-asserted-by":"publisher","first-page":"4829","DOI":"10.1007\/s10067-021-05783-8","volume":"40","author":"RW Jakes","year":"2021","unstructured":"Jakes, R. W. et al. Burden of illness associated with eosinophilic granulomatosis with polyangiitis: a systematic literature review and meta-analysis. Clin. Rheumatol. 40, 4829\u20134836 (2021).","journal-title":"Clin. Rheumatol."},{"key":"1406_CR6","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1002\/art.20077","volume":"51","author":"A Mahr","year":"2004","unstructured":"Mahr, A., Guillevin, L., Poissonnet, M. & Aym\u00e9, S. Prevalences of polyarteritis nodosa, microscopic polyangiitis, Wegener\u2019s granulomatosis, and Churg-Strauss syndrome in a French urban multiethnic population in 2000: a capture-recapture estimate. Arthritis Rheum. 51, 92\u201399 (2004).","journal-title":"Arthritis Rheum."},{"key":"1406_CR7","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1111\/j.1445-5994.2008.01672.x","volume":"38","author":"AS Ormerod","year":"2008","unstructured":"Ormerod, A. S. & Cook, M. C. Epidemiology of primary systemic vasculitis in the Australian Capital Territory and south-eastern New South Wales. Intern. Med. J. 38, 816\u2013823 (2008).","journal-title":"Intern. Med. J."},{"key":"1406_CR8","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1002\/art.40313","volume":"69","author":"A Berti","year":"2017","unstructured":"Berti, A., Cornec, D., Crowson, C. S., Specks, U. & Matteson, E. L. The epidemiology of antineutrophil cytoplasmic autoantibody-associated vasculitis in Olmsted County, Minnesota: a twenty-year US population-based study. Arthritis Rheumatol. 69, 2338\u20132350 (2017).","journal-title":"Arthritis Rheumatol."},{"key":"1406_CR9","first-page":"107","volume":"27","author":"M Gokhale","year":"2021","unstructured":"Gokhale, M. et al. Prevalence of eosinophilic granulomatosis with polyangiitis and associated health care utilization among patients with concomitant asthma in US commercial claims database. J. Clin. Rheumatol. Pract. Rep. Rheum. Musculoskelet. Dis. 27, 107\u2013113 (2021).","journal-title":"J. Clin. Rheumatol. Pract. Rep. Rheum. Musculoskelet. Dis."},{"key":"1406_CR10","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.jaip.2024.10.013","volume":"13","author":"Y Puan","year":"2025","unstructured":"Puan, Y. et al. Characteristics of severe asthma clinic patients with eosinophilic granulomatosis with polyangiitis. J. Allergy Clin. Immunol. Pract. 13, 361\u2013368.e2 (2025).","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"1406_CR11","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/j.chest.2019.11.045","volume":"157","author":"A Berti","year":"2020","unstructured":"Berti, A. et al. Eosinophilic granulomatosis with polyangiitis: clinical predictors of long-term asthma severity. Chest 157, 1086\u20131099 (2020).","journal-title":"Chest"},{"key":"1406_CR12","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.jaip.2020.07.038","volume":"9","author":"H-C Chang","year":"2021","unstructured":"Chang, H.-C., Chou, P.-C., Lai, C.-Y. & Tsai, H.-H. Antineutrophil cytoplasmic antibodies and organ-specific manifestations in eosinophilic granulomatosis with polyangiitis: a systematic review and meta-analysis. J. Allergy Clin. Immunol. Pract. 9, 445\u2013452.e6 (2021).","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"1406_CR13","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1183\/13993003.00097-2016","volume":"48","author":"V Cottin","year":"2016","unstructured":"Cottin, V. et al. Respiratory manifestations of eosinophilic granulomatosis with polyangiitis (Churg\u2013Strauss). Eur. Respir. J. 48, 1429\u20131441 (2016).","journal-title":"Eur. Respir. J."},{"key":"1406_CR14","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1159\/000484602","volume":"175","author":"V Seccia","year":"2018","unstructured":"Seccia, V. et al. Focus on the involvement of the nose and paranasal sinuses in eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome): nasal cytology reveals infiltration of eosinophils as a very common feature. Int. Arch. Allergy Immunol. 175, 61\u201369 (2018).","journal-title":"Int. Arch. Allergy Immunol."},{"key":"1406_CR15","doi-asserted-by":"publisher","first-page":"406","DOI":"10.2500\/ajr.2008.22.3204","volume":"22","author":"I Srouji","year":"2008","unstructured":"Srouji, I., Lund, V., Andrews, P. & Edwards, C. Rhinologic symptoms and quality-of-life in patients with Churg-Strauss syndrome vasculitis. Am. J. Rhinol. 22, 406\u2013409 (2008).","journal-title":"Am. J. Rhinol."},{"key":"1406_CR16","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1093\/rheumatology\/kez139","volume":"58","author":"X Pu\u00e9chal","year":"2019","unstructured":"Pu\u00e9chal, X. et al. Non-severe eosinophilic granulomatosis with polyangiitis: long-term outcomes after remission-induction trial. Rheumatology 58, 2107\u20132116 (2019).","journal-title":"Rheumatology"},{"key":"1406_CR17","doi-asserted-by":"publisher","first-page":"103338","DOI":"10.1016\/j.jaut.2024.103338","volume":"149","author":"B Sorin","year":"2024","unstructured":"Sorin, B. et al. Glucocorticoids versus glucocorticoids plus cyclophosphamide in eosinophilic granulomatosis with polyangiitis with poor-prognosis factors. J. Autoimmun. 149, 103338 (2024).","journal-title":"J. Autoimmun."},{"key":"1406_CR18","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1002\/acr2.11263","volume":"3","author":"I Doubelt","year":"2021","unstructured":"Doubelt, I. et al. Clinical manifestations and long-term outcomes of eosinophilic granulomatosis with polyangiitis in North America. ACR Open Rheumatol. 3, 404\u2013412 (2021).","journal-title":"ACR Open Rheumatol."},{"key":"1406_CR19","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.jaci.2012.05.058","volume":"131","author":"B Healy","year":"2013","unstructured":"Healy, B. et al. Antineutrophil cytoplasmic autoantibodies and myeloperoxidase autoantibodies in clinical expression of Churg-Strauss syndrome. J. Allergy Clin. Immunol. 131, 571\u2013576.e6 (2013).","journal-title":"J. Allergy Clin. Immunol."},{"key":"1406_CR20","doi-asserted-by":"publisher","first-page":"632","DOI":"10.7326\/0003-4819-143-9-200511010-00006","volume":"143","author":"R Sabl\u00e9-Fourtassou","year":"2005","unstructured":"Sabl\u00e9-Fourtassou, R. et al. Antineutrophil cytoplasmic antibodies and the Churg\u2013Strauss syndrome. Ann. Intern. Med. 143, 632\u2013638 (2005).","journal-title":"Ann. Intern. Med."},{"key":"1406_CR21","doi-asserted-by":"publisher","first-page":"2926","DOI":"10.1002\/art.21250","volume":"52","author":"RA Sinico","year":"2005","unstructured":"Sinico, R. A. et al. Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. Arthritis Rheum. 52, 2926\u20132935 (2005).","journal-title":"Arthritis Rheum."},{"key":"1406_CR22","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1002\/acr.22686","volume":"68","author":"C-A Durel","year":"2016","unstructured":"Durel, C.-A. et al. Long-term followup of a multicenter cohort of 101 patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Arthritis Care Res. 68, 374\u2013387 (2016).","journal-title":"Arthritis Care Res."},{"key":"1406_CR23","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.rmed.2010.09.011","volume":"105","author":"MM Dulohery","year":"2011","unstructured":"Dulohery, M. M., Patel, R. R., Schneider, F. & Ryu, J. H. Lung involvement in hypereosinophilic syndromes. Respir. Med. 105, 114\u2013121 (2011).","journal-title":"Respir. Med."},{"key":"1406_CR24","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/j.jaip.2019.12.011","volume":"8","author":"G Lef\u00e8vre","year":"2020","unstructured":"Lef\u00e8vre, G. et al. \u2018Idiopathic eosinophilic vasculitis\u2019: another side of hypereosinophilic syndrome? A comprehensive analysis of 117 cases in asthma-free patients. J. Allergy Clin. Immunol. Pract. 8, 1329\u20131340.e3 (2020).","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"1406_CR25","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1002\/art.22679","volume":"57","author":"P Cohen","year":"2007","unstructured":"Cohen, P. et al. Churg-Strauss syndrome with poor-prognosis factors: a prospective multicenter trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in forty-eight patients. Arthritis Rheum. 57, 686\u2013693 (2007).","journal-title":"Arthritis Rheum."},{"key":"1406_CR26","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jaut.2013.03.003","volume":"43","author":"M Samson","year":"2013","unstructured":"Samson, M. et al. Long-term outcomes of 118 patients with eosinophilic granulomatosis with polyangiitis (Churg\u2013Strauss syndrome) enrolled in two prospective trials. J. Autoimmun. 43, 60\u201369 (2013).","journal-title":"J. Autoimmun."},{"key":"1406_CR27","doi-asserted-by":"publisher","first-page":"5238","DOI":"10.1093\/rheumatology\/keaf256","volume":"64","author":"B Sorin","year":"2025","unstructured":"Sorin, B. et al. Glucocorticoids vs glucocorticoids plus cyclophosphamide in eosinophilic granulomatosis with polyangiitis without poor-prognosis factors: a target trial emulation study. Rheumatology 64, 5238\u20135244 (2025).","journal-title":"Rheumatology"},{"key":"1406_CR28","doi-asserted-by":"publisher","first-page":"193","DOI":"10.2147\/JAA.S176026","volume":"11","author":"DB Price","year":"2018","unstructured":"Price, D. B. et al. Adverse outcomes from initiation of systemic corticosteroids for asthma: long-term observational study. J. Asthma Allergy 11, 193\u2013204 (2018).","journal-title":"J. Asthma Allergy"},{"key":"1406_CR29","doi-asserted-by":"publisher","first-page":"00912","DOI":"10.1183\/23120541.00912-2023","volume":"10","author":"RW Jakes","year":"2024","unstructured":"Jakes, R. W. et al. Burden of eosinophilic granulomatosis with polyangiitis in Europe. ERJ Open Res. 10, 00912\u201302023 (2024).","journal-title":"ERJ Open Res."},{"key":"1406_CR30","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1093\/mr\/roae100","volume":"35","author":"T Ishii","year":"2025","unstructured":"Ishii, T. et al. Real-world safety and effectiveness of mepolizumab for patients with eosinophilic granulomatosis with polyangiitis in Japan: long-term observation of the MARS study. Mod. Rheumatol. 35, 505\u2013515 (2025).","journal-title":"Mod. Rheumatol."},{"key":"1406_CR31","first-page":"40","volume":"35","author":"L Benarous","year":"2017","unstructured":"Benarous, L. et al. Employment, work disability and quality of life in patients with ANCA-associated vasculitides. The EXPOVAS study. Clin. Exp. Rheumatol. 35, 40\u201346 (2017).","journal-title":"Clin. Exp. Rheumatol."},{"key":"1406_CR32","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1146\/annurev-pathol-011811-132453","volume":"8","author":"JC Jennette","year":"2013","unstructured":"Jennette, J. C., Falk, R. J., Hu, P. & Xiao, H. Pathogenesis of antineutrophil cytoplasmic autoantibody-associated small-vessel vasculitis. Annu. Rev. Pathol. 8, 139\u2013160 (2013).","journal-title":"Annu. Rev. Pathol."},{"key":"1406_CR33","doi-asserted-by":"publisher","DOI":"10.1111\/all.70215","author":"H Wilson-Morkeh","year":"2026","unstructured":"Wilson-Morkeh, H. et al. Targeting immunologic pathways in eosinophilic granulomatosis with polyangiitis: translating emerging evidence into clinical practice. Allergy https:\/\/doi.org\/10.1111\/all.70215 (2026).","journal-title":"Allergy"},{"key":"1406_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-56786-x","volume":"16","author":"CM Wortel","year":"2025","unstructured":"Wortel, C. M. et al. Anti-myeloperoxidase IgM B cells in anti-neutrophil cytoplasmic antibody-associated vasculitis. Nat. Commun. 16, 1582 (2025).","journal-title":"Nat. Commun."},{"key":"1406_CR35","first-page":"41","volume":"204","author":"B Terrier","year":"2020","unstructured":"Terrier, B. Granulomatose \u00e9osinophilique avec polyang\u00e9ite : pathog\u00e9nie et cons\u00e9quences th\u00e9rapeutiques. Bull. Acad. Natl. Med. 204, 41\u201347 (2020).","journal-title":"Bull. Acad. Natl. Med."},{"key":"1406_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12515-9","volume":"10","author":"PA Lyons","year":"2019","unstructured":"Lyons, P. A. et al. Genome-wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratified by ANCA status. Nat. Commun. 10, 5120 (2019).","journal-title":"Nat. Commun."},{"key":"1406_CR37","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/s41584-023-00958-w","volume":"19","author":"G Emmi","year":"2023","unstructured":"Emmi, G. et al. Evidence-based guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis. Nat. Rev. Rheumatol. 19, 378\u2013393 (2023).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1406_CR38","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.ejim.2015.04.022","volume":"26","author":"M Groh","year":"2015","unstructured":"Groh, M. et al. Eosinophilic granulomatosis with polyangiitis (Churg\u2013Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management. Eur. J. Intern. Med. 26, 545\u2013553 (2015).","journal-title":"Eur. J. Intern. Med."},{"key":"1406_CR39","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.jbspin.2018.06.002","volume":"86","author":"A Le Roy","year":"2019","unstructured":"Le Roy, A. et al. Angioimmunoblastic T-cell lymphoma mimicking eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Joint Bone Spine 86, 273\u2013274 (2019).","journal-title":"Joint Bone Spine"},{"key":"1406_CR40","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1056\/NEJM199402243300804","volume":"330","author":"E Cogan","year":"1994","unstructured":"Cogan, E. et al. Brief report: clonal proliferation of type 2 helper T cells in a man with the hypereosinophilic syndrome. N. Engl. J. Med. 330, 535\u2013538 (1994).","journal-title":"N. Engl. J. Med."},{"key":"1406_CR41","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1136\/ard.2008.088096","volume":"68","author":"C Mukhtyar","year":"2009","unstructured":"Mukhtyar, C. et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann. Rheum. Dis. 68, 310\u2013317 (2009).","journal-title":"Ann. Rheum. Dis."},{"key":"1406_CR42","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1136\/ard-2022-223764","volume":"83","author":"B Hellmich","year":"2024","unstructured":"Hellmich, B. et al. EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. Ann. Rheum. Dis. 83, 30\u201347 (2024).","journal-title":"Ann. Rheum. Dis."},{"key":"1406_CR43","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1002\/art.41773","volume":"73","author":"SA Chung","year":"2021","unstructured":"Chung, S. A. et al. 2021 American College of Rheumatology\/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol. 73, 1366\u20131383 (2021).","journal-title":"Arthritis Rheumatol."},{"key":"1406_CR44","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1056\/NEJMoa1702079","volume":"376","author":"ME Wechsler","year":"2017","unstructured":"Wechsler, M. E. et al. Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis. N. Engl. J. Med. 376, 1921\u20131932 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1406_CR45","doi-asserted-by":"publisher","first-page":"e361","DOI":"10.1016\/S2665-9913(24)00082-1","volume":"6","author":"RJ Hollick","year":"2024","unstructured":"Hollick, R. J. et al. Identifying key health system components associated with improved outcomes to inform the re-configuration of services for adults with rare autoimmune rheumatic diseases: a mixed-methods study. Lancet Rheumatol. 6, e361\u2013e373 (2024).","journal-title":"Lancet Rheumatol."},{"key":"1406_CR46","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1097\/00005792-199601000-00003","volume":"75","author":"L Guillevin","year":"1996","unstructured":"Guillevin, L. et al. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. Medicine 75, 17\u201328 (1996).","journal-title":"Medicine"},{"key":"1406_CR47","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1097\/MD.0b013e318205a4c6","volume":"90","author":"L Guillevin","year":"2011","unstructured":"Guillevin, L. et al. The five-factor score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine 90, 19\u201327 (2011).","journal-title":"Medicine"},{"key":"1406_CR48","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.autrev.2014.08.002","volume":"13","author":"M Samson","year":"2014","unstructured":"Samson, M. et al. Mononeuritis multiplex predicts the need for immunosuppressive or immunomodulatory drugs for EGPA, PAN and MPA patients without poor-prognosis factors. Autoimmun. Rev. 13, 945\u2013953 (2014).","journal-title":"Autoimmun. Rev."},{"key":"1406_CR49","first-page":"197","volume":"24","author":"R Padoan","year":"2018","unstructured":"Padoan, R. et al. Overall disability sum score for clinical assessment of neurological involvement in eosinophilic granulomatosis with polyangiitis. J. Clin. Rheumatol. Pract. Rep. Rheum. Musculoskelet. Dis. 24, 197\u2013202 (2018).","journal-title":"J. Clin. Rheumatol. Pract. Rep. Rheum. Musculoskelet. Dis."},{"key":"1406_CR50","doi-asserted-by":"publisher","first-page":"3350","DOI":"10.1093\/rheumatology\/kead077","volume":"62","author":"F Delestre","year":"2023","unstructured":"Delestre, F. et al. Clinico-radiological correlation and prognostic value of baseline chest computed tomography in eosinophilic granulomatosis with polyangiitis. Rheumatology 62, 3350\u20133357 (2023).","journal-title":"Rheumatology"},{"key":"1406_CR51","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1093\/rheumatology\/kes155","volume":"52","author":"J Marmursztejn","year":"2013","unstructured":"Marmursztejn, J. et al. Churg\u2013Strauss syndrome cardiac involvement evaluated by cardiac magnetic resonance imaging and positron-emission tomography: a prospective study on 20 patients. Rheumatology 52, 642\u2013650 (2013).","journal-title":"Rheumatology"},{"key":"1406_CR52","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.autrev.2015.04.013","volume":"14","author":"B Dunogu\u00e9","year":"2015","unstructured":"Dunogu\u00e9, B. et al. Impact of cardiac magnetic resonance imaging on eosinophilic granulomatosis with polyangiitis outcomes: a long-term retrospective study on 42 patients. Autoimmun. Rev. 14, 774\u2013780 (2015).","journal-title":"Autoimmun. Rev."},{"key":"1406_CR53","doi-asserted-by":"publisher","first-page":"4538","DOI":"10.1093\/rheumatology\/keab027","volume":"60","author":"E Garcia-Vives","year":"2021","unstructured":"Garcia-Vives, E., Rodriguez-Palomares, J. F., Harty, L., Solans-Laque, R. & Jayne, D. Heart disease in eosinophilic granulomatosis with polyangiitis (EGPA) patients: a screening approach proposal. Rheumatology 60, 4538\u20134547 (2021).","journal-title":"Rheumatology"},{"key":"1406_CR54","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1136\/annrheumdis-2012-201531","volume":"72","author":"F Moosig","year":"2013","unstructured":"Moosig, F. et al. A vasculitis centre based management strategy leads to improved outcome in eosinophilic granulomatosis and polyangiitis (Churg\u2013Strauss, EGPA): monocentric experiences in 150 patients. Ann. Rheum. Dis. 72, 1011\u20131017 (2013).","journal-title":"Ann. Rheum. Dis."},{"key":"1406_CR55","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1093\/rheumatology\/keae085","volume":"64","author":"X Liu","year":"2025","unstructured":"Liu, X. et al. Cardiac involvement in eosinophilic granulomatosis with polyangiitis: acute eosinophilic myocarditis and chronic inflammatory cardiomyopathy. Rheumatology 64, 722\u2013731 (2025).","journal-title":"Rheumatology"},{"key":"1406_CR56","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1002\/ejhf.989","volume":"20","author":"P Agostoni","year":"2018","unstructured":"Agostoni, P. et al. Multiparametric prognostic scores in chronic heart failure with reduced ejection fraction: a long-term comparison. Eur. J. Heart Fail. 20, 700\u2013710 (2018).","journal-title":"Eur. J. Heart Fail."},{"key":"1406_CR57","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.jchf.2018.02.001","volume":"6","author":"M Canepa","year":"2018","unstructured":"Canepa, M. et al. Performance of prognostic risk scores in chronic heart failure patients enrolled in the European Society of Cardiology heart failure long-term registry. JACC Heart Fail. 6, 452\u2013462 (2018).","journal-title":"JACC Heart Fail."},{"key":"1406_CR58","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1097\/00005792-199901000-00003","volume":"78","author":"L Guillevin","year":"1999","unstructured":"Guillevin, L. et al. Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients. Medicine 78, 26\u201337 (1999).","journal-title":"Medicine"},{"key":"1406_CR59","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/S0025-6196(25)09873-8","volume":"52","author":"LC Chumbley","year":"1977","unstructured":"Chumbley, L. C., Harrison, E. G. & DeRemee, R. A. Allergic granulomatosis and angiitis (Churg-Strauss syndrome). Report and analysis of 30 cases. Mayo Clin. Proc. 52, 477\u2013484 (1977).","journal-title":"Mayo Clin. Proc."},{"key":"1406_CR60","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1002\/1529-0131(200103)44:3<666::AID-ANR116>3.0.CO;2-A","volume":"44","author":"M Gayraud","year":"2001","unstructured":"Gayraud, M. et al. Long-term followup of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients. Arthritis Rheum. 44, 666\u2013675 (2001).","journal-title":"Arthritis Rheum."},{"key":"1406_CR61","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1056\/NEJMoa1803537","volume":"382","author":"M Walsh","year":"2020","unstructured":"Walsh, M. et al. Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis. N. Engl. J. Med. 382, 622\u2013631 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1406_CR62","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1136\/ard-2023-224343","volume":"83","author":"S Furuta","year":"2024","unstructured":"Furuta, S. et al. Reduced-dose versus high-dose glucocorticoids added to rituximab on remission induction in ANCA-associated vasculitis: predefined 2-year follow-up study. Ann. Rheum. Dis. 83, 96\u2013102 (2024).","journal-title":"Ann. Rheum. Dis."},{"key":"1406_CR63","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1056\/NEJMoa2023386","volume":"384","author":"DRW Jayne","year":"2021","unstructured":"Jayne, D. R. W., Merkel, P. A., Schall, T. J. & Bekker, P. ADVOCATE Study Group. Avacopan for the treatment of ANCA-associated vasculitis. N. Engl. J. Med. 384, 599\u2013609 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1406_CR64","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/art.41943","volume":"74","author":"A Bettiol","year":"2022","unstructured":"Bettiol, A. et al. Mepolizumab for eosinophilic granulomatosis with polyangiitis: a European multicenter observational study. Arthritis Rheumatol. 74, 295\u2013306 (2022).","journal-title":"Arthritis Rheumatol."},{"key":"1406_CR65","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1136\/ard-2023-224624","volume":"82","author":"A Cottu","year":"2023","unstructured":"Cottu, A. et al. Benralizumab for eosinophilic granulomatosis with polyangiitis. Ann. Rheum. Dis. 82, 1580\u20131586 (2023).","journal-title":"Ann. Rheum. Dis."},{"key":"1406_CR66","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1056\/NEJMoa2311155","volume":"390","author":"ME Wechsler","year":"2024","unstructured":"Wechsler, M. E. et al. Benralizumab versus mepolizumab for eosinophilic granulomatosis with polyangiitis. N. Engl. J. Med. 390, 911\u2013921 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1406_CR67","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.7326\/ANNALS-24-03947","volume":"178","author":"B Terrier","year":"2025","unstructured":"Terrier, B. et al. Rituximab versus conventional therapy for remission induction in eosinophilic granulomatosis with polyangiitis: a randomized controlled trial. Ann. Intern. Med. 178, 1249\u20131257 (2025).","journal-title":"Ann. Intern. Med."},{"key":"1406_CR68","doi-asserted-by":"publisher","first-page":"79","DOI":"10.2165\/00003088-199834010-00004","volume":"34","author":"R Richmond","year":"1998","unstructured":"Richmond, R., McMillan, T. W. & Luqmani, R. A. Optimisation of cyclophosphamide therapy in systemic vasculitis. Clin. Pharmacokinet. 34, 79\u201390 (1998).","journal-title":"Clin. Pharmacokinet."},{"key":"1406_CR69","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1100\/tsw.2002.863","volume":"2","author":"RA Brodsky","year":"2002","unstructured":"Brodsky, R. A. High dose cyclophosphamide treatment for autoimmune disorders. ScientificWorldJournal 2, 1808\u20131815 (2002).","journal-title":"ScientificWorldJournal"},{"key":"1406_CR70","doi-asserted-by":"publisher","first-page":"76","DOI":"10.7326\/0003-4819-98-1-76","volume":"98","author":"AS Fauci","year":"1983","unstructured":"Fauci, A. S., Haynes, B. F., Katz, P. & Wolff, S. M. Wegener\u2019s granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann. Intern. Med. 98, 76\u201385 (1983).","journal-title":"Ann. Intern. Med."},{"key":"1406_CR71","doi-asserted-by":"publisher","first-page":"488","DOI":"10.7326\/0003-4819-116-6-488","volume":"116","author":"GS Hoffman","year":"1992","unstructured":"Hoffman, G. S. et al. Wegener granulomatosis: an analysis of 158 patients. Ann. Intern. Med. 116, 488\u2013498 (1992).","journal-title":"Ann. Intern. Med."},{"key":"1406_CR72","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa0909169","volume":"363","author":"RB Jones","year":"2010","unstructured":"Jones, R. B. et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N. Engl. J. Med. 363, 211\u2013220 (2010).","journal-title":"N. Engl. J. Med."},{"key":"1406_CR73","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1056\/NEJMoa1213277","volume":"369","author":"U Specks","year":"2013","unstructured":"Specks, U. et al. Efficacy of remission-induction regimens for ANCA-associated vasculitis. N. Engl. J. Med. 369, 417\u2013427 (2013).","journal-title":"N. Engl. J. Med."},{"key":"1406_CR74","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","volume":"371","author":"L Guillevin","year":"2014","unstructured":"Guillevin, L. et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N. Engl. J. Med. 371, 1771\u20131780 (2014).","journal-title":"N. Engl. J. Med."},{"key":"1406_CR75","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1136\/annrheumdis-2014-206095","volume":"75","author":"AJ Mohammad","year":"2016","unstructured":"Mohammad, A. J. et al. Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg\u2013Strauss). Ann. Rheum. Dis. 75, 396\u2013401 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"1406_CR76","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1016\/j.jaip.2017.07.027","volume":"5","author":"J Thiel","year":"2017","unstructured":"Thiel, J. et al. Rituximab as induction therapy in eosinophilic granulomatosis with polyangiitis refractory to conventional immunosuppressive treatment: a 36-month follow-up analysis. J. Allergy Clin. Immunol. Pract. 5, 1556\u20131563 (2017).","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"1406_CR77","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1136\/annrheumdis-2017-211897","volume":"77","author":"G Emmi","year":"2018","unstructured":"Emmi, G. et al. Scheduled rituximab maintenance reduces relapse rate in eosinophilic granulomatosis with polyangiitis. Ann. Rheum. Dis. 77, 952\u2013954 (2018).","journal-title":"Ann. Rheum. Dis."},{"key":"1406_CR78","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-000905","volume":"5","author":"V Teixeira","year":"2019","unstructured":"Teixeira, V., Mohammad, A. J., Jones, R. B., Smith, R. & Jayne, D. Efficacy and safety of rituximab in the treatment of eosinophilic granulomatosis with polyangiitis. RMD Open 5, e000905 (2019).","journal-title":"RMD Open"},{"key":"1406_CR79","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1002\/art.41534","volume":"73","author":"A Canzian","year":"2021","unstructured":"Canzian, A. et al. Use of biologics to treat relapsing and\/or refractory eosinophilic granulomatosis with polyangiitis: data from a European collaborative study. Arthritis Rheumatol. 73, 498\u2013503 (2021).","journal-title":"Arthritis Rheumatol."},{"key":"1406_CR80","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1136\/ard-2022-222776","volume":"81","author":"A Bettiol","year":"2022","unstructured":"Bettiol, A. et al. Sequential rituximab and mepolizumab in eosinophilic granulomatosis with polyangiitis (EGPA): a European multicentre observational study. Ann. Rheum. Dis. 81, 1769\u20131772 (2022).","journal-title":"Ann. Rheum. Dis."},{"key":"1406_CR81","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa0909905","volume":"363","author":"JH Stone","year":"2010","unstructured":"Stone, J. H. et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N. Engl. J. Med. 363, 221\u2013232 (2010).","journal-title":"N. Engl. J. Med."},{"key":"1406_CR82","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1136\/annrheumdis-2016-209925","volume":"76","author":"EE van Daalen","year":"2017","unstructured":"van Daalen, E. E. et al. Effect of rituximab on malignancy risk in patients with ANCA-associated vasculitis. Ann. Rheum. Dis. 76, 1064\u20131069 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"1406_CR83","volume":"77","author":"X Pu\u00e9chal","year":"2025","unstructured":"Pu\u00e9chal, X. et al. Maintenance of remission with rituximab versus azathioprine in newly diagnosed or relapsing eosinophilic granulomatosis with polyangiitis. A prospective, randomized, controlled, double-blind trial. Arthritis Rheumatol. 77, 1765 (2025).","journal-title":"Arthritis Rheumatol."},{"key":"1406_CR84","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1093\/rheumatology\/keab046","volume":"60","author":"VG Menditto","year":"2021","unstructured":"Menditto, V. G. et al. Rituximab for eosinophilic granulomatosis with polyangiitis: a systematic review of observational studies. Rheumatology 60, 1640\u20131650 (2021).","journal-title":"Rheumatology"},{"key":"1406_CR85","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1002\/art.23198","volume":"58","author":"C Ribi","year":"2008","unstructured":"Ribi, C. et al. Treatment of Churg-Strauss syndrome without poor-prognosis factors: a multicenter, prospective, randomized, open-label study of seventy-two patients. Arthritis Rheum. 58, 586\u2013594 (2008).","journal-title":"Arthritis Rheum."},{"key":"1406_CR86","first-page":"S52","volume":"22","author":"C Metzler","year":"2004","unstructured":"Metzler, C., Hellmich, B., Gause, A., Gross, W. L. & de Groot, K. Churg Strauss syndrome \u2014 successful induction of remission with methotrexate and unexpected high cardiac and pulmonary relapse ratio during maintenance treatment. Clin. Exp. Rheumatol. 22, S52\u2013S61 (2004).","journal-title":"Clin. Exp. Rheumatol."},{"key":"1406_CR87","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0185880","volume":"12","author":"F Maritati","year":"2017","unstructured":"Maritati, F. et al. Methotrexate versus cyclophosphamide for remission maintenance in ANCA-associated vasculitis: a randomised trial. PLoS One 12, e0185880 (2017).","journal-title":"PLoS One"},{"key":"1406_CR88","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1007\/s00296-021-04961-w","volume":"41","author":"M Philobos","year":"2021","unstructured":"Philobos, M. et al. A real-world assessment of mycophenolate mofetil for remission induction in eosinophilic granulomatosis with polyangiitis. Rheumatol. Int. 41, 1811\u20131814 (2021).","journal-title":"Rheumatol. Int."},{"key":"1406_CR89","first-page":"171","volume":"38","author":"I Doubelt","year":"2020","unstructured":"Doubelt, I., Pulenzas, N., Carette, S. & Pagnoux, C. & Canadian Vasculitis Network (CanVasc). Efficacy of conventional immunosuppressants in relapsing or refractory eosinophilic granulomatosis with polyangiitis: evidence from a Canadian single-centre cohort. Clin. Exp. Rheumatol. 38, 171\u2013175 (2020).","journal-title":"Clin. Exp. Rheumatol."},{"key":"1406_CR90","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.3899\/jrheum.171352","volume":"45","author":"A Saku","year":"2018","unstructured":"Saku, A. et al. Longterm outcomes of 188 Japanese patients with eosinophilic granulomatosis with polyangiitis. J. Rheumatol. 45, 1159\u20131166 (2018).","journal-title":"J. Rheumatol."},{"key":"1406_CR91","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1002\/art.39472","volume":"68","author":"E Crickx","year":"2016","unstructured":"Crickx, E. et al. Intravenous immunoglobulin as an immunomodulating agent in antineutrophil cytoplasmic antibody-associated vasculitides: a French nationwide study of ninety-two patients. Arthritis Rheumatol. 68, 702\u2013712 (2016).","journal-title":"Arthritis Rheumatol."},{"key":"1406_CR92","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13223-023-00801-7","volume":"19","author":"N Masumoto","year":"2023","unstructured":"Masumoto, N. et al. Long-term mepolizumab treatment reduces relapse rates in super-responders with eosinophilic granulomatosis with polyangiitis. Allergy Asthma Clin. Immunol. 19, 40 (2023).","journal-title":"Allergy Asthma Clin. Immunol."},{"key":"1406_CR93","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s00415-024-12731-4","volume":"272","author":"C Fasano","year":"2024","unstructured":"Fasano, C. et al. Effectiveness and safety of intravenous immunoglobulin for peripheral neuropathy in EGPA patients: a retrospective study. J. Neurol. 272, 13 (2024).","journal-title":"J. Neurol."},{"key":"1406_CR94","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1007\/s00415-014-7618-y","volume":"262","author":"H Koike","year":"2015","unstructured":"Koike, H., Akiyama, K., Saito, T. & Sobue, G.; Research Group for IVIg for EGPA\/CSS in Japan. Intravenous immunoglobulin for chronic residual peripheral neuropathy in eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome): a multicenter, double-blind trial. J. Neurol. 262, 752\u2013759 (2015).","journal-title":"J. Neurol."},{"key":"1406_CR95","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1002\/art.1780381116","volume":"38","author":"L Guillevin","year":"1995","unstructured":"Guillevin, L. et al. Corticosteroids plus pulse cyclophosphamide and plasma exchanges versus corticosteroids plus pulse cyclophosphamide alone in the treatment of polyarteritis nodosa and Churg-Strauss syndrome patients with factors predicting poor prognosis. A prospective, randomized trial in sixty-two patients. Arthritis Rheum. 38, 1638\u20131645 (1995).","journal-title":"Arthritis Rheum."},{"key":"1406_CR96","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1182\/blood.V73.6.1504.1504","volume":"73","author":"EJ Clutterbuck","year":"1989","unstructured":"Clutterbuck, E. J., Hirst, E. M. & Sanderson, C. J. Human interleukin-5 (IL-5) regulates the production of eosinophils in human bone marrow cultures: comparison and interaction with IL-1, IL-3, IL-6, and GMCSF. Blood 73, 1504\u20131512 (1989).","journal-title":"Blood"},{"key":"1406_CR97","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1182\/blood.V78.10.2542.2542","volume":"78","author":"Y Yamaguchi","year":"1991","unstructured":"Yamaguchi, Y. et al. Analysis of the survival of mature human eosinophils: interleukin-5 prevents apoptosis in mature human eosinophils. Blood 78, 2542\u20132547 (1991).","journal-title":"Blood"},{"key":"1406_CR98","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1084\/jem.167.5.1737","volume":"167","author":"Y Yamaguchi","year":"1988","unstructured":"Yamaguchi, Y. et al. Highly purified murine interleukin 5 (IL-5) stimulates eosinophil function and prolongs in vitro survival. IL-5 as an eosinophil chemotactic factor. J. Exp. Med. 167, 1737\u20131742 (1988).","journal-title":"J. Exp. Med."},{"key":"1406_CR99","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1164\/rccm.200208-789OC","volume":"167","author":"PT Flood-Page","year":"2003","unstructured":"Flood-Page, P. T., Menzies-Gow, A. N., Kay, A. B. & Robinson, D. S. Eosinophil\u2019s role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am. J. Respir. Crit. Care Med. 167, 199\u2013204 (2003).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"1406_CR100","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1056\/NEJMoa0808991","volume":"360","author":"P Haldar","year":"2009","unstructured":"Haldar, P. et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N. Engl. J. Med. 360, 973\u2013984 (2009).","journal-title":"N. Engl. J. Med."},{"key":"1406_CR101","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","volume":"371","author":"HG Ortega","year":"2014","unstructured":"Ortega, H. G. et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N. Engl. J. Med. 371, 1198\u20131207 (2014).","journal-title":"N. Engl. J. Med."},{"key":"1406_CR102","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","volume":"388","author":"ER Bleecker","year":"2016","unstructured":"Bleecker, E. R. et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting \u03b22-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet 388, 2115\u20132127 (2016).","journal-title":"Lancet"},{"key":"1406_CR103","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","volume":"388","author":"JM FitzGerald","year":"2016","unstructured":"FitzGerald, J. M. et al. Benralizumab, an anti-interleukin-5 receptor \u03b1 monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 388, 2128\u20132141 (2016).","journal-title":"Lancet"},{"key":"1406_CR104","doi-asserted-by":"publisher","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","volume":"376","author":"P Nair","year":"2017","unstructured":"Nair, P. et al. Oral glucocorticoid-sparing effect of benralizumab in severe asthma. N. Engl. J. Med. 376, 2448\u20132458 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1406_CR105","doi-asserted-by":"publisher","first-page":"863","DOI":"10.2147\/JAA.S319572","volume":"14","author":"MZ Kayser","year":"2021","unstructured":"Kayser, M. Z. et al. Real-world multicenter experience with mepolizumab and benralizumab in the treatment of uncontrolled severe eosinophilic asthma over 12 months. J. Asthma Allergy 14, 863\u2013871 (2021).","journal-title":"J. Asthma Allergy"},{"key":"1406_CR106","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1111\/cea.14112","volume":"52","author":"D Charles","year":"2022","unstructured":"Charles, D. et al. Real-world efficacy of treatment with benralizumab, dupilumab, mepolizumab and reslizumab for severe asthma: a systematic review and meta-analysis. Clin. Exp. Allergy 52, 616\u2013627 (2022).","journal-title":"Clin. Exp. Allergy"},{"key":"1406_CR107","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/S2213-2600(21)00097-7","volume":"9","author":"JK Han","year":"2021","unstructured":"Han, J. K. et al. Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir. Med. 9, 1141\u20131153 (2021).","journal-title":"Lancet Respir. Med."},{"key":"1406_CR108","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/j.jaci.2021.08.030","volume":"149","author":"C Bachert","year":"2022","unstructured":"Bachert, C. et al. Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: a randomized, placebo-controlled trial. J. Allergy Clin. Immunol. 149, 1309\u20131317.e12 (2022).","journal-title":"J. Allergy Clin. Immunol."},{"key":"1406_CR109","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/S2213-2600(15)00367-7","volume":"3","author":"DB Price","year":"2015","unstructured":"Price, D. B. et al. Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study. Lancet Respir. Med. 3, 849\u2013858 (2015).","journal-title":"Lancet Respir. Med."},{"key":"1406_CR110","first-page":"1249","volume":"27","author":"CF Bell","year":"2021","unstructured":"Bell, C. F., Blauer-Peterson, C. & Mao, J. Burden of illness and costs associated with eosinophilic granulomatosis with polyangiitis: evidence from a managed care database in the United States. J. Manag. Care Spec. Pharm. 27, 1249\u20131259 (2021).","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"1406_CR111","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1056\/NEJMoa1812185","volume":"380","author":"FL Kuang","year":"2019","unstructured":"Kuang, F. L. et al. Benralizumab for PDGFRA-negative hypereosinophilic syndrome. N. Engl. J. Med. 380, 1336\u20131346 (2019).","journal-title":"N. Engl. J. Med."},{"key":"1406_CR112","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1136\/gutjnl-2023-330337","volume":"72","author":"ES Dellon","year":"2023","unstructured":"Dellon, E. S. et al. Mepolizumab for treatment of adolescents and adults with eosinophilic oesophagitis: a multicentre, randomised, double-blind, placebo-controlled clinical trial. Gut 72, 1828\u20131837 (2023).","journal-title":"Gut"},{"key":"1406_CR113","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1016\/j.jaci.2018.11.041","volume":"143","author":"J Steinfeld","year":"2019","unstructured":"Steinfeld, J. et al. Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis. J. Allergy Clin. Immunol. 143, 2170\u20132177 (2019).","journal-title":"J. Allergy Clin. Immunol."},{"key":"1406_CR114","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1002\/art.43146","volume":"77","author":"ME Wechsler","year":"2025","unstructured":"Wechsler, M. E. et al. Long-term safety and efficacy of mepolizumab in eosinophilic granulomatosis with polyangiitis. Arthritis Rheumatol. 77, 1052\u20131062 (2025).","journal-title":"Arthritis Rheumatol."},{"key":"1406_CR115","doi-asserted-by":"publisher","first-page":"1204444","DOI":"10.3389\/fimmu.2023.1204444","volume":"14","author":"S Nolasco","year":"2023","unstructured":"Nolasco, S. et al. Effectiveness and safety of anti-IL-5\/R\u03b1 biologics in eosinophilic granulomatosis with polyangiitis: a two-year multicenter observational study. Front. Immunol. 14, 1204444 (2023).","journal-title":"Front. Immunol."},{"key":"1406_CR116","doi-asserted-by":"publisher","first-page":"1457202","DOI":"10.3389\/fimmu.2024.1457202","volume":"15","author":"M Shiomi","year":"2024","unstructured":"Shiomi, M. et al. Long-term efficacy of mepolizumab in patients with eosinophilic granulomatosis with polyangiitis: a propensity score matching analysis in the multicenter REVEAL cohort study. Front. Immunol. 15, 1457202 (2024).","journal-title":"Front. Immunol."},{"key":"1406_CR117","doi-asserted-by":"publisher","first-page":"101806","DOI":"10.1016\/j.reuma.2024.10.007","volume":"21","author":"F Rubi\u00f1o Ju\u00e1rez","year":"2025","unstructured":"Rubi\u00f1o Ju\u00e1rez, F. et al. Mepolizumab efficacy and safety in patients with eosinophilic granulomatosis with polyangiitis in real practice: data from a Spanish retrospective multicentric register from rheumatology departments. Reumatol. Clin. 21, 101806 (2025).","journal-title":"Reumatol. Clin."},{"key":"1406_CR118","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1159\/000526410","volume":"183","author":"B \u00d6zdel \u00d6zt\u00fcrk","year":"2022","unstructured":"\u00d6zdel \u00d6zt\u00fcrk, B. et al. Effectiveness of low-dose mepolizumab in the treatment of eosinophilic granulomatosis with polyangiitis (EGPA): a real-life experience. Int. Arch. Allergy Immunol. 183, 1281\u20131290 (2022).","journal-title":"Int. Arch. Allergy Immunol."},{"key":"1406_CR119","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1093\/mr\/roaf064","volume":"36","author":"R Watanabe","year":"2025","unstructured":"Watanabe, R. et al. Concordance between treatment guideline and daily practice in the management of eosinophilic granulomatosis with polyangiitis: a cross-sectional web-questionnaire survey. Mod. Rheumatol. 36, 68\u201376 (2025).","journal-title":"Mod. Rheumatol."},{"key":"1406_CR120","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s13075-022-02845-3","volume":"24","author":"M Ueno","year":"2022","unstructured":"Ueno, M. et al. Safety and effectiveness of mepolizumab therapy in remission induction therapy for eosinophilic granulomatosis with polyangiitis: a retrospective study. Arthritis Res. Ther. 24, 159 (2022).","journal-title":"Arthritis Res. Ther."},{"key":"1406_CR121","doi-asserted-by":"publisher","first-page":"3466","DOI":"10.1074\/jbc.M210665200","volume":"278","author":"T Shinkawa","year":"2003","unstructured":"Shinkawa, T. et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J. Biol. Chem. 278, 3466\u20133473 (2003).","journal-title":"J. Biol. Chem."},{"key":"1406_CR122","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/j.jaci.2010.04.004","volume":"125","author":"R Kolbeck","year":"2010","unstructured":"Kolbeck, R. et al. MEDI-563, a humanized anti-IL-5 receptor \u03b1\u00a0mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. J. Allergy Clin. Immunol. 125, 1344\u20131353.e2 (2010).","journal-title":"J. Allergy Clin. Immunol."},{"key":"1406_CR123","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1177\/1753465816667659","volume":"10","author":"F Menzella","year":"2016","unstructured":"Menzella, F., Lusuardi, M., Galeone, C., Facciolongo, N. & Zucchi, L. The clinical profile of benralizumab in the management of severe eosinophilic asthma. Ther. Adv. Respir. Dis. 10, 534\u2013548 (2016).","journal-title":"Ther. Adv. Respir. Dis."},{"key":"1406_CR124","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/j.jaci.2013.05.020","volume":"132","author":"M Laviolette","year":"2013","unstructured":"Laviolette, M. et al. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. J. Allergy Clin. Immunol. 132, 1086\u20131096.e5 (2013).","journal-title":"J. Allergy Clin. Immunol."},{"key":"1406_CR125","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1016\/j.jaci.2018.01.008","volume":"141","author":"R Sehmi","year":"2018","unstructured":"Sehmi, R. et al. Benralizumab attenuates airway eosinophilia in prednisone-dependent asthma. J. Allergy Clin. Immunol. 141, 1529\u20131532.e8 (2018).","journal-title":"J. Allergy Clin. Immunol."},{"key":"1406_CR126","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.alit.2020.02.002","volume":"69","author":"H Nagase","year":"2020","unstructured":"Nagase, H., Ueki, S. & Fujieda, S. The roles of IL-5 and anti-IL-5 treatment in eosinophilic diseases: asthma, eosinophilic granulomatosis with polyangiitis, and eosinophilic chronic rhinosinusitis. Allergol. Int. 69, 178\u2013186 (2020).","journal-title":"Allergol. Int."},{"key":"1406_CR127","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13223-020-00507-0","volume":"17","author":"A Ghassemian","year":"2021","unstructured":"Ghassemian, A., Park, J. J., Tsoulis, M. W. & Kim, H. Targeting the IL-5 pathway in eosinophilic asthma: a comparison of mepolizumab to benralizumab in the reduction of peripheral eosinophil counts. Allergy Asthma Clin. Immunol. 17, 3 (2021).","journal-title":"Allergy Asthma Clin. Immunol."},{"key":"1406_CR128","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/cea.13809","volume":"51","author":"AI Papaioannou","year":"2021","unstructured":"Papaioannou, A. I., Fouka, E., Papakosta, D., Papiris, S. & Loukides, S. Switching between biologics in severe asthma patients. When the first choice is not proven to be the best. Clin. Exp. Allergy 51, 221\u2013227 (2021).","journal-title":"Clin. Exp. Allergy"},{"key":"1406_CR129","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1016\/j.jaip.2022.02.037","volume":"10","author":"FL Kuang","year":"2022","unstructured":"Kuang, F. L. et al. Benralizumab completely depletes gastrointestinal tissue eosinophils and improves symptoms in eosinophilic gastrointestinal disease. J. Allergy Clin. Immunol. Pract. 10, 1598\u20131605.e2 (2022).","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"1406_CR130","doi-asserted-by":"publisher","DOI":"10.1016\/j.ard.2025.06.2131","author":"PA Merkel","year":"2025","unstructured":"Merkel, P. A. et al. Two-year efficacy and safety of anti-interleukin-5\/receptor therapy for eosinophilic granulomatosis with polyangiitis. Ann. Rheum. Dis. https:\/\/doi.org\/10.1016\/j.ard.2025.06.2131 (2025).","journal-title":"Ann. Rheum. Dis."},{"key":"1406_CR131","doi-asserted-by":"publisher","first-page":"00451","DOI":"10.1183\/23120541.00451-2020","volume":"6","author":"AM Nanzer","year":"2020","unstructured":"Nanzer, A. M. et al. Steroid-sparing effects of benralizumab in patients with eosinophilic granulomatosis with polyangiitis. ERJ Open Res. 6, 00451\u201302020 (2020).","journal-title":"ERJ Open Res."},{"key":"1406_CR132","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1016\/j.jaip.2020.09.054","volume":"9","author":"VP Guntur","year":"2021","unstructured":"Guntur, V. P. et al. Benralizumab as a steroid-sparing treatment option in eosinophilic granulomatosis with polyangiitis. J. Allergy Clin. Immunol. Pract. 9, 1186\u20131193.e1 (2021).","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"1406_CR133","doi-asserted-by":"publisher","first-page":"e707","DOI":"10.1016\/S2665-9913(23)00243-6","volume":"5","author":"A Bettiol","year":"2023","unstructured":"Bettiol, A. et al. Benralizumab for eosinophilic granulomatosis with polyangiitis: a retrospective, multicentre, cohort study. Lancet Rheumatol. 5, e707\u2013e715 (2023).","journal-title":"Lancet Rheumatol."},{"key":"1406_CR134","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.jaip.2024.01.006","volume":"12","author":"AM Nanzer","year":"2024","unstructured":"Nanzer, A. M. et al. Long-term effectiveness of benralizumab in eosinophilic granulomatosis with polyangiitis. J. Allergy Clin. Immunol. Pract. 12, 724\u2013732 (2024).","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"1406_CR135","doi-asserted-by":"publisher","first-page":"557","DOI":"10.2147\/JAA.S461800","volume":"17","author":"C M\u00fcmmler","year":"2024","unstructured":"M\u00fcmmler, C. et al. Benralizumab reduces respiratory exacerbations and oral glucocorticosteroid dose in patients with severe asthma and eosinophilic granulomatosis with polyangiitis. J. Asthma Allergy 17, 557\u2013572 (2024).","journal-title":"J. Asthma Allergy"},{"key":"1406_CR136","doi-asserted-by":"publisher","first-page":"103398","DOI":"10.1016\/j.jaut.2025.103398","volume":"153","author":"I Mattioli","year":"2025","unstructured":"Mattioli, I. et al. Mepolizumab versus benralizumab for eosinophilic granulomatosis with polyangiitis (EGPA): a European real-life retrospective comparative study. J. Autoimmun. 153, 103398 (2025).","journal-title":"J. Autoimmun."},{"key":"1406_CR137","doi-asserted-by":"publisher","DOI":"10.3389\/falgy.2022.881218","volume":"3","author":"M D\u2019Amato","year":"2022","unstructured":"D\u2019Amato, M. et al. Benralizumab in patients with severe eosinophilic asthma with and without chronic rhinosinusitis with nasal polyps: an ANANKE study post-hoc analysis. Front. Allergy 3, 881218 (2022).","journal-title":"Front. Allergy"},{"key":"1406_CR138","doi-asserted-by":"publisher","first-page":"3650","DOI":"10.1016\/j.jaip.2023.07.024","volume":"11","author":"MC Liu","year":"2023","unstructured":"Liu, M. C. et al. Mepolizumab in patients with severe asthma and comorbidities: 1-year REALITI-a analysis. J. Allergy Clin. Immunol. Pract. 11, 3650\u20133661.e3 (2023).","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"1406_CR139","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1164\/rccm.202305-0808OC","volume":"209","author":"ME Wechsler","year":"2024","unstructured":"Wechsler, M. E. et al. Association between T2-related comorbidities and effectiveness of biologics in severe asthma. Am. J. Respir. Crit. Care Med. 209, 262\u2013272 (2024).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"1406_CR140","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1111\/all.16618","volume":"80","author":"F Schleich","year":"2025","unstructured":"Schleich, F. et al. Mepolizumab effectiveness in severe asthma with\/without chronic rhinosinusitis with nasal polyps: real-world pooled analysis. Allergy 80, 2557\u20132571 (2025).","journal-title":"Allergy"},{"key":"1406_CR141","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1002\/acr2.11571","volume":"5","author":"B Terrier","year":"2023","unstructured":"Terrier, B. et al. Clinical benefit of mepolizumab in eosinophilic granulomatosis with polyangiitis for patients with and without a vasculitic phenotype. ACR Open Rheumatol. 5, 354\u2013363 (2023).","journal-title":"ACR Open Rheumatol."},{"key":"1406_CR142","doi-asserted-by":"publisher","first-page":"e97","DOI":"10.1164\/rccm.202109-2093ST","volume":"204","author":"SB Khatri","year":"2021","unstructured":"Khatri, S. B. et al. Use of fractional exhaled nitric oxide to guide the treatment of asthma: an official American Thoracic Society clinical practice guideline. Am. J. Respir. Crit. Care Med. 204, e97\u2013e109 (2021).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"1406_CR143","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S2213-2600(25)00037-2","volume":"13","author":"FL Meulmeester","year":"2025","unstructured":"Meulmeester, F. L. et al. Inflammatory and clinical risk factors for asthma attacks (ORACLE2): a patient-level meta-analysis of control groups of 22 randomised trials. Lancet Respir. Med. 13, 505\u2013516 (2025).","journal-title":"Lancet Respir. Med."},{"key":"1406_CR144","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.jaip.2015.12.014","volume":"4","author":"M Latorre","year":"2016","unstructured":"Latorre, M. et al. Asthma control and airway inflammation in patients with eosinophilic granulomatosis with polyangiitis. J. Allergy Clin. Immunol. Pract. 4, 512\u2013519 (2016).","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"1406_CR145","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1093\/rheumatology\/kes171","volume":"51","author":"B Jakiela","year":"2012","unstructured":"Jakiela, B. et al. Increased production of IL-5 and dominant Th2-type response in airways of Churg-Strauss syndrome patients. Rheumatology 51, 1887\u20131893 (2012).","journal-title":"Rheumatology"},{"key":"1406_CR146","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1016\/j.jaip.2018.04.033","volume":"6","author":"FL Kuang","year":"2018","unstructured":"Kuang, F. L. et al. Long-term clinical outcomes of high-dose mepolizumab treatment for hypereosinophilic syndrome. J. Allergy Clin. Immunol. Pract. 6, 1518\u20131527.e5 (2018).","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"1406_CR147","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1007\/s00296-020-04523-6","volume":"40","author":"LD Condreay","year":"2020","unstructured":"Condreay, L. D. et al. Pharmacogenetic investigation of efficacy response to mepolizumab in eosinophilic granulomatosis with polyangiitis. Rheumatol. Int. 40, 1301\u20131307 (2020).","journal-title":"Rheumatol. Int."},{"key":"1406_CR148","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1093\/rheumatology\/keu427","volume":"54","author":"PC Grayson","year":"2015","unstructured":"Grayson, P. C. et al. Value of commonly measured laboratory tests as biomarkers of disease activity and predictors of relapse in eosinophilic granulomatosis with polyangiitis. Rheumatology 54, 1351\u20131359 (2015).","journal-title":"Rheumatology"},{"key":"1406_CR149","doi-asserted-by":"publisher","DOI":"10.1002\/art.43398","author":"PK Nair","year":"2025","unstructured":"Nair, P. K. et al. The effect of benralizumab and mepolizumab on use of oral glucocorticoids in patients with eosinophilic granulomatosis with polyangiitis. Arthritis Rheumatol. https:\/\/doi.org\/10.1002\/art.43398 (2025).","journal-title":"Arthritis Rheumatol."},{"key":"1406_CR150","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1111\/all.15934","volume":"79","author":"M Caminati","year":"2024","unstructured":"Caminati, M. et al. Eosinophilic granulomatosis with polyangiitis onset in severe asthma patients on monoclonal antibodies targeting type 2 inflammation: report from the European EGPA study group. Allergy 79, 516\u2013519 (2024).","journal-title":"Allergy"},{"key":"1406_CR151","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.70096","volume":"7","author":"ME Wechsler","year":"2025","unstructured":"Wechsler, M. E. et al. Discontinuation of oral glucocorticoids and achievement of remission in patients with eosinophilic granulomatosis with polyangiitis treated with benralizumab or mepolizumab. ACR Open Rheumatol. 7, e70096 (2025).","journal-title":"ACR Open Rheumatol."},{"key":"1406_CR152","first-page":"4937","volume":"64","author":"P Delvino","year":"2025","unstructured":"Delvino, P. et al. Impact of mepolizumab on the AAV-PRO questionnaire in eosinophilic granulomatosis with polyangiitis: data from a European multicentre study. Rheumatology 64, 4937\u20134947 (2025).","journal-title":"Rheumatology"},{"key":"1406_CR153","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.jaip.2022.02.006","volume":"10","author":"MM Chen","year":"2022","unstructured":"Chen, M. M. et al. An international, retrospective study of off-label biologic use in the treatment of hypereosinophilic syndromes. J. Allergy Clin. Immunol. Pract. 10, 1217\u20131228.e3 (2022).","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"1406_CR154","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1016\/j.jaip.2022.02.014","volume":"10","author":"DJ Jackson","year":"2022","unstructured":"Jackson, D. J. et al. Benralizumab effectiveness in severe asthma is independent of previous biologic use. J. Allergy Clin. Immunol. Pract. 10, 1534\u20131544.e4 (2022).","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"1406_CR155","doi-asserted-by":"publisher","first-page":"273","DOI":"10.2147\/JAA.S438981","volume":"17","author":"P Cameli","year":"2024","unstructured":"Cameli, P. et al. Sustained effectiveness of benralizumab in na\u00efve and biologics-experienced severe eosinophilic asthma patients: results from the ANANKE study. J. Asthma Allergy 17, 273\u2013290 (2024).","journal-title":"J. Asthma Allergy"},{"key":"1406_CR156","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.jaip.2018.01.025","volume":"6","author":"E Heffler","year":"2018","unstructured":"Heffler, E. et al. Inhaled corticosteroids safety and adverse effects in patients with asthma. J. Allergy Clin. Immunol. Pract. 6, 776\u2013781 (2018).","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"1406_CR157","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S0140-6736(23)02284-5","volume":"403","author":"DJ Jackson","year":"2024","unstructured":"Jackson, D. J. et al. Reduction of daily maintenance inhaled corticosteroids in patients with severe eosinophilic asthma treated with benralizumab (SHAMAL): a randomised, multicentre, open-label, phase 4 study. Lancet 403, 271\u2013281 (2024).","journal-title":"Lancet"},{"key":"1406_CR158","doi-asserted-by":"publisher","first-page":"5108","DOI":"10.1093\/rheumatology\/keaf201","volume":"64","author":"L Moroni","year":"2025","unstructured":"Moroni, L. et al. Step-down treatment with mepolizumab for eosinophilic granulomatosis with polyangiitis: a real-life single-centre study. Rheumatology 64, 5108\u20135111 (2025).","journal-title":"Rheumatology"},{"key":"1406_CR159","doi-asserted-by":"publisher","first-page":"2100396","DOI":"10.1183\/13993003.00396-2021","volume":"59","author":"WC Moore","year":"2022","unstructured":"Moore, W. C. et al. Stopping versus continuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study). Eur. Respir. J. 59, 2100396 (2022).","journal-title":"Eur. Respir. J."},{"key":"1406_CR160","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1111\/bcp.15002","volume":"88","author":"D Singh","year":"2022","unstructured":"Singh, D. et al. A Phase 1 study of the long-acting anti-IL-5 monoclonal antibody GSK3511294 in patients with asthma. Br. J. Clin. Pharmacol. 88, 702\u2013712 (2022).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"1406_CR161","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1056\/NEJMoa2406673","volume":"391","author":"DJ Jackson","year":"2024","unstructured":"Jackson, D. J. et al. Twice-yearly depemokimab in severe asthma with an eosinophilic phenotype. N. Engl. J. Med. 391, 2337\u20132349 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1406_CR162","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/S0140-6736(25)00197-7","volume":"405","author":"P Gevaert","year":"2025","unstructured":"Gevaert, P. et al. Efficacy and safety of twice per year depemokimab in chronic rhinosinusitis with nasal polyps (ANCHOR-1 and ANCHOR-2): phase 3, randomised, double-blind, parallel trials. Lancet 405, 911\u2013926 (2025).","journal-title":"Lancet"},{"key":"1406_CR163","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1002\/bcp.70439","volume":"92","author":"L Yang","year":"2026","unstructured":"Yang, L. et al. SHR-1703, a novel long-acting anti-interleukin-5 monoclonal antibody, in asthma patients: a randomized, double-blind, placebo-controlled phase 1 study. Br. J. Clin. Pharmacol. 92, 1673\u20131684 (2026).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"1406_CR164","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/S2213-2600(15)00042-9","volume":"3","author":"M Castro","year":"2015","unstructured":"Castro, M. et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir. Med. 3, 355\u2013366 (2015).","journal-title":"Lancet Respir. Med."},{"key":"1406_CR165","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/S2213-2600(19)30372-8","volume":"8","author":"JA Bernstein","year":"2020","unstructured":"Bernstein, J. A. et al. Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma: results from two phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respir. Med. 8, 461\u2013474 (2020).","journal-title":"Lancet Respir. Med."},{"key":"1406_CR166","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/j.anai.2021.01.035","volume":"126","author":"LA Manka","year":"2021","unstructured":"Manka, L. A. et al. Efficacy and safety of reslizumab in the treatment of eosinophilic granulomatosis with polyangiitis. Ann. Allergy Asthma Immunol. 126, 696\u2013701.e1 (2021).","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"1406_CR167","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1111\/all.14221","volume":"75","author":"I Agache","year":"2020","unstructured":"Agache, I. et al. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI guidelines \u2014 recommendations on the use of biologicals in severe asthma. Allergy 75, 1023\u20131042 (2020).","journal-title":"Allergy"},{"key":"1406_CR168","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1056\/NEJMoa1804093","volume":"378","author":"KF Rabe","year":"2018","unstructured":"Rabe, K. F. et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N. Engl. J. Med. 378, 2475\u20132485 (2018).","journal-title":"N. Engl. J. Med."},{"key":"1406_CR169","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","volume":"394","author":"C Bachert","year":"2019","unstructured":"Bachert, C. et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet 394, 1638\u20131650 (2019).","journal-title":"Lancet"},{"key":"1406_CR170","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","volume":"389","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt, A. et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet 389, 2287\u20132303 (2017).","journal-title":"Lancet"},{"key":"1406_CR171","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1056\/NEJMoa2205982","volume":"387","author":"ES Dellon","year":"2022","unstructured":"Dellon, E. S. et al. Dupilumab in adults and adolescents with eosinophilic esophagitis. N. Engl. J. Med. 387, 2317\u20132330 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1406_CR172","doi-asserted-by":"publisher","first-page":"3393","DOI":"10.1016\/j.jaip.2024.09.015","volume":"12","author":"C Hopkins","year":"2024","unstructured":"Hopkins, C. et al. Dupilumab versus mepolizumab for chronic rhinosinusitis with nasal polyposis: an indirect treatment comparison. J. Allergy Clin. Immunol. Pract. 12, 3393\u20133401.e15 (2024).","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"1406_CR173","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1002\/alr.23466","volume":"15","author":"M Dorling","year":"2025","unstructured":"Dorling, M. et al. Switching biologics in chronic rhinosinusitis with nasal polyps: a multicenter Canadian experience. Int. Forum Allergy Rhinol. 15, 166\u2013173 (2025).","journal-title":"Int. Forum Allergy Rhinol."},{"key":"1406_CR174","doi-asserted-by":"publisher","first-page":"2695","DOI":"10.1016\/j.jaip.2022.05.019","volume":"10","author":"ME Wechsler","year":"2022","unstructured":"Wechsler, M. E. et al. Effect of dupilumab on blood eosinophil counts in patients with asthma, chronic rhinosinusitis with nasal polyps, atopic dermatitis, or eosinophilic esophagitis. J. Allergy Clin. Immunol. Pract. 10, 2695\u20132709 (2022).","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"1406_CR175","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1136\/ard-2023-224756","volume":"82","author":"B Molina","year":"2023","unstructured":"Molina, B. et al. Dupilumab for relapsing or refractory sinonasal and\/or asthma manifestations in eosinophilic granulomatosis with polyangiitis: a European retrospective study. Ann. Rheum. Dis. 82, 1587\u20131593 (2023).","journal-title":"Ann. Rheum. Dis."},{"key":"1406_CR176","doi-asserted-by":"publisher","first-page":"104761","DOI":"10.1016\/j.amjoto.2025.104761","volume":"47","author":"G Gramellini","year":"2025","unstructured":"Gramellini, G. et al. Adjunctive dual biologic therapy for persistent nasal symptoms in eosinophilic granulomatosis with polyangiitis (EGPA). Am. J. Otolaryngol. 47, 104761 (2025).","journal-title":"Am. J. Otolaryngol."},{"key":"1406_CR177","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1056\/NEJMoa1009705","volume":"364","author":"WW Busse","year":"2011","unstructured":"Busse, W. W. et al. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N. Engl. J. Med. 364, 1005\u20131015 (2011).","journal-title":"N. Engl. J. Med."},{"key":"1406_CR178","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1056\/NEJMoa1215372","volume":"368","author":"M Maurer","year":"2013","unstructured":"Maurer, M. et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N. Engl. J. Med. 368, 924\u2013935 (2013).","journal-title":"N. Engl. J. Med."},{"key":"1406_CR179","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1056\/NEJMoa2034975","volume":"384","author":"A Menzies-Gow","year":"2021","unstructured":"Menzies-Gow, A. et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N. Engl. J. Med. 384, 1800\u20131809 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1406_CR180","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1056\/NEJMoa2414482","volume":"392","author":"BJ Lipworth","year":"2025","unstructured":"Lipworth, B. J. et al. Tezepelumab in adults with severe chronic rhinosinusitis with nasal polyps. N. Engl. J. Med. 392, 1178\u20131188 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1406_CR181","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1186\/s12931-024-02888-x","volume":"25","author":"N Vincent-Galti\u00e9","year":"2024","unstructured":"Vincent-Galti\u00e9, N. et al. Tezepelumab for refractory eosinophilic granulomatosis with polyangiitis-related asthma. Respir. Res. 25, 272 (2024).","journal-title":"Respir. Res."},{"key":"1406_CR182","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.resinv.2025.04.004","volume":"63","author":"N Watatani","year":"2025","unstructured":"Watatani, N. et al. Effectiveness of tezepelumab in preventing relapse of eosinophilic granulomatosis with polyangiitis: a case report. Respir. Investig. 63, 469\u2013471 (2025).","journal-title":"Respir. Investig."},{"key":"1406_CR183","volume":"76","author":"M Poux","year":"2024","unstructured":"Poux, M. et al. Tezepelumab for relapsing or refractory eosinophilic granulomatosis with polyangiitis: a European retrospective study. Arthritis Rheumatol. 76, 1595 (2024).","journal-title":"Arthritis Rheumatol."},{"key":"1406_CR184","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1016\/j.chest.2025.05.015","volume":"168","author":"AM Nanzer","year":"2025","unstructured":"Nanzer, A. M. et al. Tezepelumab in patients with eosinophilic granulomatosis with polyangiitis after suboptimal response to anti-IL-5\/5R therapy. Chest 168, 1093\u20131096 (2025).","journal-title":"Chest"},{"key":"1406_CR185","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1001\/jamadermatol.2024.2131","volume":"160","author":"A Blauvelt","year":"2024","unstructured":"Blauvelt, A. et al. Cendakimab in patients with moderate to severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 160, 856\u2013864 (2024).","journal-title":"JAMA Dermatol."},{"key":"1406_CR186","doi-asserted-by":"publisher","first-page":"EVIDoa2500095","DOI":"10.1056\/EVIDoa2500095","volume":"4","author":"ES Dellon","year":"2025","unstructured":"Dellon, E. S. et al. Cendakimab in adults and adolescents with eosinophilic esophagitis. NEJM Evid. 4, EVIDoa2500095 (2025).","journal-title":"NEJM Evid."},{"key":"1406_CR187","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1056\/NEJMoa2024257","volume":"385","author":"ME Wechsler","year":"2021","unstructured":"Wechsler, M. E. et al. Efficacy and safety of itepekimab in patients with moderate-to-severe asthma. N. Engl. J. Med. 385, 1656\u20131668 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1406_CR188","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1111\/jdv.20388","volume":"39","author":"JI Silverberg","year":"2025","unstructured":"Silverberg, J. I. et al. Efficacy and safety of tozorakimab in moderate-to-severe atopic dermatitis: a phase 2a randomized controlled trial (FRONTIER-2). J. Eur. Acad. Dermatol. Venereol. 39, 1126\u20131133 (2025).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"1406_CR189","doi-asserted-by":"publisher","first-page":"2402231","DOI":"10.1183\/13993003.02231-2024","volume":"66","author":"D Singh","year":"2025","unstructured":"Singh, D. et al. A phase 2a trial of the IL-33 monoclonal antibody tozorakimab in patients with COPD: FRONTIER-4. Eur. Respir. J. 66, 2402231 (2025).","journal-title":"Eur. Respir. J."},{"key":"1406_CR190","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.jaci.2021.03.044","volume":"148","author":"SG Kelsen","year":"2021","unstructured":"Kelsen, S. G. et al. Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: a randomized clinical trial. J. Allergy Clin. Immunol. 148, 790\u2013798 (2021).","journal-title":"J. Allergy Clin. Immunol."},{"key":"1406_CR191","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.ekir.2023.01.039","volume":"8","author":"FB Cortazar","year":"2023","unstructured":"Cortazar, F. B. et al. Renal recovery for patients with ANCA-associated vasculitis and low eGFR in the ADVOCATE trial of avacopan. Kidney Int. Rep. 8, 860\u2013870 (2023).","journal-title":"Kidney Int. Rep."},{"key":"1406_CR192","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.11795","volume":"7","author":"U Specks","year":"2025","unstructured":"Specks, U. et al. Treatment with avacopan in patients with respiratory tract manifestations of antineutrophil cytoplasmic antibody-associated vasculitis. ACR Open Rheumatol. 7, e11795 (2025).","journal-title":"ACR Open Rheumatol."},{"key":"1406_CR193","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1093\/ndt\/gfae020","volume":"39","author":"A Chalkia","year":"2024","unstructured":"Chalkia, A. et al. Avacopan for ANCA-associated vasculitis with hypoxic pulmonary haemorrhage. Nephrol. Dial. Transplant. 39, 1473\u20131482 (2024).","journal-title":"Nephrol. Dial. Transplant."},{"key":"1406_CR194","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2026-100221","volume":"394","author":"C Baraniuk","year":"2026","unstructured":"Baraniuk, C. Trial paper is retracted as FDA keeps scrutiny on controversial vasculitis drug. BMJ 394, e100221 (2026).","journal-title":"BMJ"},{"key":"1406_CR195","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/eji.1830260723","volume":"26","author":"J Elsner","year":"1996","unstructured":"Elsner, J., Oppermann, M. & Kapp, A. Detection of C5a receptors on human eosinophils and inhibition of eosinophil effector functions by anti-C5a receptor (CD88) antibodies. Eur. J. Immunol. 26, 1560\u20131564 (1996).","journal-title":"Eur. J. Immunol."},{"key":"1406_CR196","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1111\/all.15670","volume":"78","author":"AV Wiese","year":"2023","unstructured":"Wiese, A. V. et al. C5aR1 activation in mice controls inflammatory eosinophil recruitment and functions in allergic asthma. Allergy 78, 1893\u20131908 (2023).","journal-title":"Allergy"},{"key":"1406_CR197","doi-asserted-by":"publisher","DOI":"10.1111\/all.16616","author":"C Dong","year":"2025","unstructured":"Dong, C. et al. Role for complement C5 in eosinophilic inflammation of severe asthma. Allergy https:\/\/doi.org\/10.1111\/all.16616 (2025).","journal-title":"Allergy"},{"key":"1406_CR198","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/s41584-024-01153-1","volume":"20","author":"A Virtanen","year":"2024","unstructured":"Virtanen, A. et al. JAK inhibitor selectivity: new opportunities, better drugs? Nat. Rev. Rheumatol. 20, 649\u2013665 (2024).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1406_CR199","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2023.109275","volume":"251","author":"S Faguer","year":"2023","unstructured":"Faguer, S. et al. JAK inhibition for CD3- CD4+ lymphocytic-variant hypereosinophilic syndrome. Clin. Immunol. 251, 109275 (2023).","journal-title":"Clin. Immunol."},{"key":"1406_CR200","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1136\/annrheumdis-2021-220484","volume":"80","author":"Y Liu","year":"2021","unstructured":"Liu, Y. et al. Tofacitinib for the treatment of antineutrophil cytoplasm antibody-associated vasculitis: a pilot study. Ann. Rheum. Dis. 80, 1631\u20131633 (2021).","journal-title":"Ann. Rheum. Dis."},{"key":"1406_CR201","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.3899\/jrheum.221219","volume":"50","author":"L Linde","year":"2023","unstructured":"Linde, L., Faurschou, M., Krintel, S. B. & Baslund, B. Response to treatment with tofacitinib in 11 patients with refractory granulomatosis with polyangiitis. J. Rheumatol. 50, 1088\u20131089 (2023).","journal-title":"J. Rheumatol."},{"key":"1406_CR202","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaf397","author":"Y Liu","year":"2025","unstructured":"Liu, Y. et al. Tofacitinib in combination with glucocorticoids in the treatment of eosinophilic granulomatosis with polyangiitis: a pilot study of 11 cases. Rheumatology https:\/\/doi.org\/10.1093\/rheumatology\/keaf397 (2025).","journal-title":"Rheumatology"},{"key":"1406_CR203","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41584-023-01062-9","volume":"20","author":"Z Szekanecz","year":"2024","unstructured":"Szekanecz, Z. et al. Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician. Nat. Rev. Rheumatol. 20, 101\u2013115 (2024).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1406_CR204","unstructured":"Global Initiative for Asthma. 2025 GINA Strategy Report. https:\/\/ginasthma.org\/2025-gina-strategy-report\/ (2025)."},{"key":"1406_CR205","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1002\/alr.22741","volume":"11","author":"RR Orlandi","year":"2021","unstructured":"Orlandi, R. R. et al. International consensus statement on allergy and rhinology: rhinosinusitis 2021. Int. Forum Allergy Rhinol. 11, 213\u2013739 (2021).","journal-title":"Int. Forum Allergy Rhinol."},{"key":"1406_CR206","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1111\/all.15982","volume":"79","author":"PW Hellings","year":"2024","unstructured":"Hellings, P. W. et al. EUFOREA\/EPOS2020 statement on the clinical considerations for chronic rhinosinusitis with nasal polyps care. Allergy 79, 1123\u20131133 (2024).","journal-title":"Allergy"},{"key":"1406_CR207","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1002\/alr.23536","volume":"15","author":"N Kumar","year":"2025","unstructured":"Kumar, N. et al. Eosinophilic granulomatosis with polyangiitis: a real-world study of biologics and sinus surgery use for managing nasal polyposis. Int. Forum Allergy Rhinol. 15, 608\u2013615 (2025).","journal-title":"Int. Forum Allergy Rhinol."},{"key":"1406_CR208","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.1016\/j.jaip.2022.04.034","volume":"10","author":"NC Thomson","year":"2022","unstructured":"Thomson, N. C., Polosa, R. & Sin, D. D. Cigarette smoking and asthma. J. Allergy Clin. Immunol. Pract. 10, 2783\u20132797 (2022).","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"1406_CR209","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1002\/art.41722","volume":"73","author":"F Maritati","year":"2021","unstructured":"Maritati, F. et al. Occupational exposures and smoking in eosinophilic granulomatosis with polyangiitis: a case-control study. Arthritis Rheumatol. 73, 1694\u20131702 (2021).","journal-title":"Arthritis Rheumatol."},{"key":"1406_CR210","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1136\/annrheumdis-2019-215882","volume":"79","author":"V Furer","year":"2020","unstructured":"Furer, V. et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann. Rheum. Dis. 79, 39\u201352 (2020).","journal-title":"Ann. Rheum. Dis."},{"key":"1406_CR211","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3390\/vaccines10010013","volume":"10","author":"G Costanzo","year":"2021","unstructured":"Costanzo, G. et al. Eosinophilic granulomatosis with polyangiitis relapse after COVID-19 vaccination: a case report. Vaccines 10, 13 (2021).","journal-title":"Vaccines"},{"key":"1406_CR212","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.3390\/vaccines11081335","volume":"11","author":"L Mencarelli","year":"2023","unstructured":"Mencarelli, L. et al. Eosinophilic granulomatosis with polyangiitis after mRNA-1273 SARS-CoV-2 vaccine. Vaccines 11, 1335 (2023).","journal-title":"Vaccines"},{"key":"1406_CR213","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.8217","volume":"11","author":"M Jafarpour","year":"2023","unstructured":"Jafarpour, M., Daneshvar, S., Eftekharsadat, A. T., Khabbazi, A. & Pourbagherian, O. Eosinophilic granulomatosis with polyangiitis following flu guard influenza vaccination: a case report. Clin. Case Rep. 11, e8217 (2023).","journal-title":"Clin. Case Rep."},{"key":"1406_CR214","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1002\/art.42646","volume":"75","author":"MB Humphrey","year":"2023","unstructured":"Humphrey, M. B. et al. 2022 American College of Rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheumatol. 75, 2088\u20132102 (2023).","journal-title":"Arthritis Rheumatol."},{"key":"1406_CR215","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1093\/ejendo\/lvae146","volume":"191","author":"J Paccou","year":"2024","unstructured":"Paccou, J. et al. Prevention and treatment of glucocorticoid-induced osteoporosis in adults: recommendations from the European Calcified Tissue Society. Eur. J. Endocrinol. 191, G1\u2013G17 (2024).","journal-title":"Eur. J. Endocrinol."},{"key":"1406_CR216","doi-asserted-by":"publisher","first-page":"j2099","DOI":"10.1136\/bmj.j2099","volume":"357","author":"J Hippisley-Cox","year":"2017","unstructured":"Hippisley-Cox, J., Coupland, C. & Brindle, P. Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study. BMJ 357, j2099 (2017).","journal-title":"BMJ"},{"key":"1406_CR217","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.rdc.2017.04.013","volume":"43","author":"G Bandoli","year":"2017","unstructured":"Bandoli, G., Palmsten, K., Forbess Smith, C. J. & Chambers, C. D. A review of systemic corticosteroid use in pregnancy and the risk of select pregnancy and birth outcomes. Rheum. Dis. Clin. North Am. 43, 489\u2013502 (2017).","journal-title":"Rheum. Dis. Clin. North Am."},{"key":"1406_CR218","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1001\/jamainternmed.2025.6367","volume":"186","author":"E-Y Choi","year":"2026","unstructured":"Choi, E.-Y. et al. Oral corticosteroid use during pregnancy and the risk of gestational diabetes. JAMA Intern. Med. 186, 224\u2013232 (2026).","journal-title":"JAMA Intern. Med."},{"key":"1406_CR219","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/S2213-2600(24)00174-7","volume":"13","author":"J Naftel","year":"2025","unstructured":"Naftel, J. et al. An international consensus on the use of asthma biologics in pregnancy. Lancet Respir. Med. 13, 80\u201391 (2025).","journal-title":"Lancet Respir. Med."},{"key":"1406_CR220","doi-asserted-by":"publisher","first-page":"2952","DOI":"10.1182\/blood.V79.11.2952.bloodjournal79112952","volume":"79","author":"R Sehmi","year":"1992","unstructured":"Sehmi, R. et al. Interleukin-5 selectively enhances the chemotactic response of eosinophils obtained from normal but not eosinophilic subjects. Blood 79, 2952\u20132959 (1992).","journal-title":"Blood"},{"key":"1406_CR221","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1196\/annals.1361.053","volume":"1051","author":"B Hellmich","year":"2005","unstructured":"Hellmich, B., Csernok, E. & Gross, W. L. Proinflammatory cytokines and autoimmunity in Churg-Strauss syndrome. Ann. N. Y. Acad. Sci. 1051, 121\u2013131 (2005).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"1406_CR222","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2500\/108854199778681486","volume":"20","author":"A Tsukadaira","year":"1999","unstructured":"Tsukadaira, A. et al. Eosinophil active cytokines and surface analysis of eosinophils in Churg-Strauss syndrome. Allergy Asthma Proc. 20, 39\u201344 (1999).","journal-title":"Allergy Asthma Proc."},{"key":"1406_CR223","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1093\/rheumatology\/ken175","volume":"47","author":"RJ Pepper","year":"2008","unstructured":"Pepper, R. J. et al. Rituximab is effective in the treatment of refractory Churg\u2013Strauss syndrome and is associated with diminished T-cell interleukin-5 production. Rheumatology 47, 1104\u20131105 (2008).","journal-title":"Rheumatology"},{"key":"1406_CR224","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.143366","volume":"6","author":"ME Kotas","year":"2021","unstructured":"Kotas, M. E. et al. A role for IL-33-activated ILC2s in eosinophilic vasculitis. JCI Insight 6, e143366 (2021).","journal-title":"JCI Insight"},{"key":"1406_CR225","doi-asserted-by":"publisher","first-page":"405","DOI":"10.4155\/fmc.16.4","volume":"8","author":"K Vale","year":"2016","unstructured":"Vale, K. Targeting the JAK-STAT pathway in the treatment of \u2018Th2-high\u2019 severe asthma. Future Med. Chem. 8, 405\u2013419 (2016).","journal-title":"Future Med. Chem."},{"key":"1406_CR226","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1136\/annrheumdis-2021-221794","volume":"81","author":"PC Grayson","year":"2022","unstructured":"Grayson, P. C. et al. 2022 American College of Rheumatology\/European Alliance of Associations for Rheumatology classification criteria for eosinophilic granulomatosis with polyangiitis. Ann. Rheum. Dis. 81, 309\u2013314 (2022).","journal-title":"Ann. Rheum. Dis."},{"key":"1406_CR227","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1136\/ard.2008.101279","volume":"68","author":"C Mukhtyar","year":"2009","unstructured":"Mukhtyar, C. et al. Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann. Rheum. Dis. 68, 1827\u20131832 (2009).","journal-title":"Ann. Rheum. Dis."},{"key":"1406_CR228","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1136\/annrheumdis-2017-212713","volume":"77","author":"JC Robson","year":"2018","unstructured":"Robson, J. C. et al. Validation of the ANCA-associated vasculitis patient-reported outcomes (AAV-PRO) questionnaire. Ann. Rheum. Dis. 77, 1157\u20131164 (2018).","journal-title":"Ann. Rheum. Dis."}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41584-026-01406-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-026-01406-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-026-01406-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:02:07Z","timestamp":1787313727000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41584-026-01406-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,4]]},"references-count":228,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1406"],"URL":"https:\/\/doi.org\/10.1038\/s41584-026-01406-1","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,4]]},"assertion":[{"value":"24 June 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"F.R. declares speaker fees and consultancy fees for participation in advisory boards from AstraZeneca and GlaxoSmithKline. A.E. declares consulting and advisory board fees from AstraZeneca related to this topic. G.E. declares consulting, advisory board participation, and speaker\u2019s fees from GlaxoSmithKline and AstraZeneca related to this topic. M.G. declares personal fees from GlaxoSmithKline and AstraZeneca outside the submitted work. A.M.N. declares payment or honoraria for lectures and educational events from AstraZeneca, GlaxoSmithKline, Sanofi and Chiesi, and support for attending conferences from AstraZeneca and GlaxoSmithKline. U.S. declares receipt of consulting or advisory board honoraria from Amgen, Argenx, AstraZeneca, Boehringer-Ingelheim, ChemoCentryx, CSL Vifor and Novartis, and research grant support from Amgen, AstraZeneca, Bristol-Myers Squibb, Genentech, GlaxoSmithKline, NorthStar Medical Radioisotopes, Novartis and NS-Pharma. M.E.W. declares receipt of consulting and\/or advisory honoraria from Abbvie, Allakos, Apogee, Areteia Therapeutics, Arrowhead Pharmaceutical, Avalo Therapeutics, Belenos Bio, Celldex, Connect Biopharma, Eli Lilly, Enveda Therapeutics, Equillium, General Medicines, Gilead, Jasper Therapeutics, Kinaset, Kymera, Merck, MyBiometry, Pfizer, Pharming, Phylaxis, Pulmatrix, Rapt Therapeutics, Recludix Pharma, Roche\/Genentech, Sentien, Sound Biologics, Tetherex Pharmaceuticals, Uniquity Bio, Verona Pharma and Zurabio; M.E.W. declares that he has received consulting, advising and\/or speaking honoraria from AstraZeneca, Amgen, Regeneron, GlaxoSmithkline, Sanofi\/Genzyme and is doing research sponsored by them; M.E.W. has received stock options from Cellergy Pharma Inc and has received consulting honoraria and stock options and is doing research sponsored by Upstream Bio. A.V. declares receipt of consulting fees from GlaxoSmithKline and AstraZeneca. B.T. declares consulting, advisory board participation, and speaker\u2019s fees from AstraZeneca and GlaxoSmithKline related to this topic. A.C. declares no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}